Abstract: The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.

Abstract: The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs.

Abstract: Methods for the prevention and treatment of skin damage, and, arising from exposure to ultraviolet or solar radiation, using lipoic acid in a dermatologically acceptable carrier that can be topically applied to the skin areas. A fat-soluble fatty acid ester of ascorbic acid such as palmityl ascorbate and/or tocotrienol and/or an &agr;-hydroxy acid such as glycolic acid is applied with the lipoic acid and/or its derivatives in some embodiments.

Abstract: The invention is directed to non-hygroscopic oral pharmaceutical compositions of a salt of valproic acid, and processes for preparing the compositions. The non-hygroscopic pharmaceutical compositions are prepared by blending a hygroscopic salt of valproic acid, carbomer, and a non-hygroscopic additive.

Abstract: A storage and delivery system for directly applying nitric oxide to a user includes a portable and disposable capsule and a source of nitric oxide gas disposed within the cavity. Gas flow control apparatus controls the flow of nitric oxide gas from the cavity. Gas flow initiation apparatus allows the user to initiate the flow of nitric oxide gas. The encapsulated nitric oxide gas is applied by positioning the capsule proximate to the objective site of the user and initiating flow of the nitric oxide gas.

Abstract: A cosmetic containing at least 1% by weight of hydrofluoroether having a viscosity of less than 5 mPa·s at 25° C., which is represented by the general formula (1): CnHmF1—O—CxHyFz  (1) wherein n is a number of 1 to 12, m is a number of 0 to 25, 1 is a number of 0 to 11, m+1=2n+1, x is a number of 1 to 12, y is a number of 0 to 25, z is a number of 0 to 11, and y+z=2x+1, provided that m and y are not be simultaneously zero, and 1 and z are not be simultaneously zero, gives no environment disruption, is highly safe for the skin and improves the feeling in use.

Abstract: A pharmaceutical composition for treatment of Parkinson's disease comprising a compound of levodopa dissolved in a non-degradative solvent which allows transdermal administrtion of levodopa. The compound of levodopa is an alkyl-ester of levodopa and the solvent is a formulation comprising a substantially non-aqueous solvent, a transdermal enchancer and a detergent. The alkyl-ester of levodopa is preferably levodopa-ethyl-ester (LDEE).

Abstract: The invention concerns a composition for a softening lotion which is liquid at a temperature of at least 5° C. and which is meant to be used in treating an absorbent paper product. In the invention, this composition comprises: (a) from 1 to 10% by wt. of a component essentially containing a quaternary ammonium compound; (b) from 5 to 99% by wt. of an aqueous emollient component which contains, as active substances: (i) one or more saturated linear fatty alcohols having at least 16 carbon atoms, (ii) one or more waxy esters having a total of at least 24 carbon atoms and, where called for, (iii) one or more nonionic and/or amphoteric emulsifiers; and (c) a balance to 100% by wt. of the required amount of a solvent of the type polyol, mineral oil or their mixtures. The invention relates to the manufacture of absorbent paper products.

Abstract: A dermal or transdermal therapeutic system comprising a sheet-like substrate or reservoir containing readily volatile auxiliary agents or active agents, which substrate or reservoir is covered on one of its sides with a backing layer impermeable to the ingredients and on the opposite side with a detachable, likewise impermeable protective layer to prevent loss of ingredients during prolonged storage, is characterized in that both the backing layer and the protective layer are made of plastic film which is on both sides with vapour-deposited metal

Abstract: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.

Abstract: The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.

Abstract: A topical composition suitable for application to skin comprising an amount of antioxidant action vitamin and vitamin precursor sufficient to bring about an effect selected from the group consisting of a level of vitamin on the skin significantly above the amount of vitamin on normal vitamin untreated skin for a period of treating four hours after application of the said vitamin containing composition, a reduction of lipid peroxide levels brought about by an insult to the skin wherein the skin is treated with the said vitamin containing composition prior to said insult, a level of skin vitamin which is significantly above the level of vitamin on the skin brought about by oral ingestion of the vitamin, or a combination of any of a, b, or c.

Abstract: Methods, compositions and drug delivery systems are provided for the transdermal administration of a pharmacologically active amine. The active agent is administered with a hydroxide-releasing agent that serves as a permeation enhancer. Exemplary hydroxide-releasing agents are inorganic hydroxides, inorganic oxides, and alkali metal or alkaline earth metal salts of weak acids. Inorganic hydroxides include, for example, ammonium hydroxide, alkali metal hydroxides and alkaline earth metal hydroxides, such as sodium hydroxide, calcium hydroxide, potassium hydroxide, magnesium hydroxide, and the like.

Abstract: This invention relates to a topical composition for treating amino acid based substrates comprising a protected nucleophilic compound having the formula R—(Nu—Pr)m where R is a functional group, Nu is a nucleophile, and Pr is a phosphorus-containing protecting group, and m is an integer between 1 and 6. The invention further relates to systems which comprise this protected nucleophilic compound and an activating mechanism. The protected nucleophilic compounds of the present invention may be used in hair care compositions, textile care compositions, laundry care compositions, deodorant compositions, skin care compositions, cosmetic compositions, oral care compositions, and animal care compositions.

Abstract: The invention relates to novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives. The invention more specifically relates to compositions in the form of a patch comprising a therapeutically efficacious amount of a derivative of 2-isoxazole-8-aminotetraline, especially 1,2,3,4-tetrahydro-8(5-isoxazolyl)N-N-diisopropyl-2-naphtalenamine. The invention also relates to a 2-isoxazole-8-aminotetralin derivative, especially 1,2,3,4-tetrahydro-8-(5-isoxazolyl)-N,N-diisopropyl-2-naphtalenamine, which is used to produce a medicament which can be administered transdermally to treat irritable bowel syndrome.

Abstract: A new metered unit dose comprising 40 &mgr;g or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.

Abstract: A cosmetic composition which provides a semi-permanent, crosslinked film on a keratinous substrate, comprising a film-forming polymer having functional groups capable of cross-linking upon exposure to a cross-linking agent reactive with the functional groups; a cross-linking agent reactive with the functional groups of the film-forming polymer; a dissipatable blocking agent which is operable prior to dissipation, to block the cross-linking agent from cross-linking the functional groups of the film-forming polymer, and which, after dissipation, leaves the cross-linking agent free to cross-link the functional groups of the film-forming polymer.

Abstract: Method for the prevention of colonic adenomas in mammals at risk of developing them by administering to such mammals an effective colonic adenoma preventive amount of ursodiol or a pharmaceutically acceptable salt conjugation product thereof.

Abstract: The invention relates to pharmaceutical dosage forms with rapid disintegration in the mouth and to their process of preparation. These pharmaceutical dosage forms comprise at least one active principle dispersed in a mixture of excipients and are characterized in that the mixture of excipients comprises at least one weakly compressible diluting agent other than trehalose and a copolymer of 1-vinylpyrrolidin-2-one and of vinyl acetate. Applications: oral administration of a great many active principles (analgesics, antispasmodics, agents used in gastroenterology, agents for combating motion sickness, antimigraines, &bgr;-blockers, antihistaminics, antibiotics or antibacterials, antivertigos, hypnotics, and the like).

Abstract: A method of forming particles comprises accelerating a stream comprising a liquid; and vibrating the stream, to form particles. The particle may have a diameter that is smaller than the diameter of the nozzle used to form the stream, allowing for the formation of micro- and nano-sized particle.